4.3 Article

Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients

期刊

LEUKEMIA RESEARCH
卷 37, 期 12, 页码 1690-1696

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.09.015

关键词

MYBL2; Prognostic factors; MicroRNAs; Acute myeloid leukemia

资金

  1. Instituto de Salud Carlos III [FIS PS09/01828, CM09/00038, CM10/00321]
  2. Red Tematica de Investigacion Cooperativa en Cancer [RD06/0020/0031]
  3. Ministerio de Ciencia e Innovacion [BES2008-0080539]
  4. Generalitat Valenciana VALi+d [ACIF/2011/189, Prometeo 2011/025]
  5. X Contratos de investigacion para postresidentes-IIS La Fe
  6. MRC [MR/K01076X/1] Funding Source: UKRI
  7. Medical Research Council [MR/K01076X/1] Funding Source: researchfish

向作者/读者索取更多资源

The MYBL2 gene encodes a transcription factor implicated in cell proliferation and maturation whose amplification or overexpression has been associated with different human malignancies, suggesting that it could be implicated in tumorigenesis. We analyzed MYBL2 expression and its prognostic value in 291 patients with de novo acute myeloid leukemia (AML) and we also evaluated its association with microRNAs 29 and 30 families. MYBL2 expression in AML patients was increased relative to CD34+ cells. Moreover, MYBL2 overexpression was associated with lower expression of miR-30a (P=0.024), miR-30b (P=0.021) and miR-30c (P=0.009). Multivariate analysis showed that MYBL2 expression was an independent factor for disease-free survival (HR 3.0, 95% CI 1.5-6.0, P=0.002) and cumulative incidence of relapse (HR 2.6,95% CI 1.2-5.6, P=0.015) in patients with an intermediate-risk karyotype. In conclusion, our data showed that MYBL2 expression analysis could be useful to define subgroups of patients with poor prognosis. (C) 2013 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据